Royce & Associates LP Acquires 24,085 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Royce & Associates LP grew its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 18.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 155,803 shares of the biotechnology company’s stock after purchasing an additional 24,085 shares during the quarter. Royce & Associates LP owned approximately 0.58% of Arcturus Therapeutics worth $3,616,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new position in Arcturus Therapeutics in the 1st quarter worth about $40,000. nVerses Capital LLC bought a new position in Arcturus Therapeutics in the third quarter worth approximately $42,000. Quest Partners LLC increased its holdings in Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 3,579 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock worth $156,000 after buying an additional 1,800 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Up 1.6 %

Shares of Arcturus Therapeutics stock opened at $16.27 on Tuesday. The company has a market cap of $440.75 million, a P/E ratio of -7.79 and a beta of 2.64. The firm’s 50 day moving average price is $20.54 and its 200-day moving average price is $23.93. Arcturus Therapeutics Holdings Inc. has a 52-week low of $14.93 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. The business had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period in the prior year, the firm posted ($0.61) earnings per share. As a group, equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. The trade was a 2.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Buy” and a consensus price target of $71.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.